<DOC>
	<DOCNO>NCT00126360</DOCNO>
	<brief_summary>This randomize study compare use Anastrozole continue radiotherapy breast cancer compare use anastrozole irradiation .</brief_summary>
	<brief_title>STARS Breast Trial ( Study Anastrozole Radiotherapy Sequencing Pilot )</brief_title>
	<detailed_description>Adjuvant radiotherapy well establish primary modality enhance local control breast cancer . The use adjuvant hormone therapy tamoxifen show improve local control relatively minor amount enhance local control adjuvant radiotherapy . There however , conflict vitro clinical data regard effect different sequence tamoxifen radiotherapy term local control enhancement radiotherapy toxicity . Aromatase inhibitor anastrazole establish class drug superior tamoxifen control estrogen dependent breast cancer overall well tolerate exception great bone loss . As key question whether sequence aromatase inhibitor anastrozole alters local control act enhancer radiation breast cancer cell kill , therefore aim study compare 3 month anastrozole prior radiotherapy versus 3 month anastrozole radiotherapy specific objective reduce baseline ratio in- field radiotherapy failure 6 % 3 % .This pilot study preliminary plan long term study investigate local failure . For pilot period 6 month contribute centre open provide good test recruitment match estimate . 100 patient provide good sample compare 270 tamoxifen treat woman breast boost study quality life . It also provide 95 % CI proportion comply woman order Â± 5 % 85 90 % woman comply .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Age 18 year . No upper limit . Post total mastectomy lumpectomy . All plan surgery complete . Margins clear ( tumour contacting inked margin ) Tumour oestrogen progesterone receptor positive Planned dose irradiate volume least biological equivalent 45 Gy 25 fraction . ECOG 02 Patients post menopausal use criterion ATAC study . Written inform consent Previous radiotherapy area treat . Previous invasive malignancy within 5 year current breast cancer diagnosis exception cervix insitu skin cancer melanoma . Patients clinical evidence metastatic disease . Previous hormonal breast therapy . Ongoing hormone replacement therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Timing Radiotherapy</keyword>
	<keyword>Local Control</keyword>
</DOC>